FRI0595 EPIDEMIOLOGY AND COMPLICATIONS OF HOSPITALIZED PATIENTS WITH ADULT ONSET STILL'S DISEASE IN UNITED STATES: A NATIONWIDE ESTIMATE
Results: In 2013, 1410 US patients were coded with the ICD-9 code 714.2 and, after excluding concomitant rheumatic disease diagnoses as per protocol, 1265 AOSD patients were analyzed. AOSD patients had a mean age of 53.8 (SD -18.1) years and a median age of 54 years. 70.4% were females. The racial/ethnic distribution showed that 61.6% white, 13.9% African American and 17.3% Hispanic patients were affected. 56.9% were hospitalized in urban teaching hospitals. The Mid-Atlantic census division had the highest number of patients -240 (Figure) . 35 (2.8%) of patients developed Macrophage Activating Syndrome (MAS). 30 (2.4%) patients had other severe complications of AOSD like disseminated intravascular coagulation (DIC) and thrombotic thrombocytopenic purpura (TTP). Median length of stay was 4 days and median hospital charges were $31,400 (Table) . There were 35 inpatient deaths (mortality 2.8%): 71.4% of deaths were in females, 50% in Asians, and 71.4% were in patients in the 54-67 age group. Conclusions: In hospitalized American AOSD patients, the average age was higher than previously thought. This may indicate an aging population with a higher number of comorbidities that justify hospitalization. Mortality increased with age and was higher among women and Asians. To our knowledge, this is the largest epidemiological study of AOSD today in the USA. Background: Approximately in 5 to 10% of FMF patients there is insufficient response and/or intolerance to colchicine treatment. Several reports have pointed out the efficacy of IL-1 blockade in colchicine resistant FMF subgroup. Objectives: To review the patients followed in our center with FMF who received Anakinra, an anti-IL-1 receptor antagonist, in terms of outcome and side effects. Methods: 43 FMF patients who were treated with Anakinra were retrospectively
